Leveraging advances in biological understanding to inform combination decision-making

Published: 10 September 2020
Interview
Michael Quigley
Michael Quigley

Michael Quigley is the Senior Vice President of Research Biology at Gilead, overseeing the company’s biology teams and responsible for delivering on a preclinical pipeline from target identification and validation through lead molecule optimization and preclinical development studies in viral, fibrotic and inflammatory diseases as well as both hematologic and solid tumors. Mike joined Gilead in February of 2020 from Bristol-Myers Squibb where most recently he was Vice President and Head, Tumor Microenvironment Modulation Thematic Research Center and Site Head of the Redwood City, California location. Prior to joining Bristol-Myers Squibb, Mike led teams in Oncology Discovery at MedImmune and Janssen. Mike received his PhD in Immunology at Duke University and completed his post-doctoral studies at the Dana-Farber Cancer Institute, Department of Pediatric Oncology.

Read now